MCID: SRC027
MIFTS: 57

Sarcoma, Synovial

Categories: Cancer diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Sarcoma, Synovial

MalaCards integrated aliases for Sarcoma, Synovial:

Name: Sarcoma, Synovial 57 13 13 44 40
Synovial Sarcoma 12 76 53 59 37 29 15 73
Synovialosarcoma 59
Sarcoma Synovial 55

Characteristics:

Orphanet epidemiological data:

59
synovial sarcoma
Inheritance: Not applicable; Age of onset: All ages;

HPO:

32
sarcoma, synovial:
Inheritance somatic mutation


Classifications:



External Ids:

OMIM 57 300813
Disease Ontology 12 DOID:5485
MeSH 44 D013584
NCIt 50 C3400
SNOMED-CT 68 63211008
Orphanet 59 ORPHA3273
UMLS via Orphanet 74 C0039101
ICD10 via Orphanet 34 C49.9
MedGen 42 C0039101
KEGG 37 H00050
SNOMED-CT via HPO 69 124975008 302851001 49496001
UMLS 73 C0039101

Summaries for Sarcoma, Synovial

NIH Rare Diseases : 53 Synovial sarcoma is a rare and aggressive soft tissue sarcoma. In the early stages of the condition, it may cause no noticeable signs or symptoms. However, as the tumor grows larger, affected people may notice a lump or swelling. In some cases, the tumor can limit range of motion or cause numbness and/or pain if it presses on nearby nerves. Although synovial sarcoma does not have a clearly defined cause, genetic factors are believed to influence the development of this disease. Cells in these tumors are usually characterized by the presence of a translocation involving chromosomes X and 18. This translocation is specific to synovial sarcoma and is often used to diagnose the condition. Treatment generally includes a combination of surgery, radiation therapy and/or chemotherapy.

MalaCards based summary : Sarcoma, Synovial, also known as synovial sarcoma, is related to biphasic synovial sarcoma and monophasic synovial sarcoma. An important gene associated with Sarcoma, Synovial is SSX1 (SSX Family Member 1), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Endometrial cancer. The drugs Mechlorethamine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and bone, and related phenotypes are synovial sarcoma and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A synovium cancer which develops in the synovial membrane of the joints.

OMIM : 57 Synovial sarcomas, which represent approximately 10% of all soft tissue sarcomas, are aggressive spindle cell sarcomas containing in some cases areas of epithelial differentiation. They consistently show a specific t(X;18)(p11.2;q11.2), which usually represents either of 2 gene fusions, SYT (600192)-SSX1 (312820) or SYT-SSX2 (300192), encoding putative transcriptional proteins differing at 13 amino acid positions (summary by Ladanyi et al., 2002). Synovial sarcoma, according to the experience of Enzinger and Weiss (1983), is the fourth most common type of soft tissue sarcoma. It usually develops in adolescents and young adults, is more common in males than in females, and has no racial predilection. (300813)

Wikipedia : 76 A synovial sarcoma (also known as: malignant synovioma) is a rare form of cancer which occurs primarily... more...

Related Diseases for Sarcoma, Synovial

Diseases related to Sarcoma, Synovial via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 250)
# Related Disease Score Top Affiliating Genes
1 biphasic synovial sarcoma 34.0 CDH1 MUC1 SSX1 VIM
2 monophasic synovial sarcoma 34.0 KRT7 MUC1 SSX1 VIM
3 epithelioid cell synovial sarcoma 32.3 SSX1 SSX2B
4 synovium cancer 32.0 SS18 SSX1 SSX2B SSX3 SSX4
5 spindle cell synovial sarcoma 31.9 CALB2 KRT7 SS18 SSX1 SSX2 SSX2B
6 sarcoma 30.8 CTNNB1 KIT MDM2 SS18 SSX1 SSX2
7 leiomyosarcoma 30.6 KIT MDM2 VIM
8 epithelioid sarcoma 30.6 KRT7 MUC1 VIM
9 malignant peripheral nerve sheath tumor 30.5 KIT MDM2 MUC1 VIM
10 spindle cell sarcoma 30.4 KRT7 MDM2 MUC1 VIM
11 ewing sarcoma 30.3 CDH1 IGF1R KIT MDM2 SS18 VIM
12 liposarcoma 30.2 CALB2 HMGA2 MDM2 VIM
13 sarcomatoid renal cell carcinoma 30.1 CDH1 KIT MUC1
14 perineurioma 30.1 KIT MUC1 VIM
15 hemangiopericytoma, malignant 30.1 MDM2 MUC1 VIM
16 adenocarcinoma 30.0 CDH1 CTNNB1 KIT MUC1
17 cavernous hemangioma 30.0 KIT KRT7 MUC1 VIM
18 embryonal sarcoma 30.0 CTNNB1 KIT MDM2 VIM
19 thyroid cancer 30.0 CDH1 CTNNB1 HMGA2 KIT KRT19
20 mesothelioma, malignant 30.0 CALB2 KRT7 MUC1 VIM
21 papillary carcinoma 30.0 CDH1 KRT19 KRT7 MUC1
22 renal cell carcinoma, nonpapillary 29.7 CDH1 KIT KRT19 KRT7 MUC1 VIM
23 adenoid cystic carcinoma 29.6 CDH1 CTNNB1 KIT KRT19 KRT7 MUC1
24 fibrous synovial sarcoma 12.4
25 mediastinum synovial sarcoma 11.2
26 ceruminoma 10.3 KIT KRT7
27 jejunal cancer 10.3 KIT KRT7
28 reticular perineurioma 10.3 KIT MUC1
29 mesenchymoma 10.3 HMGA2 MDM2
30 solid adenocarcinoma with mucin production 10.3 KRT7 MUC1
31 pseudo-meigs syndrome 10.3 CALB2 CDH1
32 lung acinar adenocarcinoma 10.3 CTNNB1 KRT7
33 cervical adenoma malignum 10.3 HMGA2 KRT7
34 linitis plastica 10.3 CDH1 KRT7
35 endosalpingiosis 10.3 KRT7 MUC1
36 ovarian fibrothecoma 10.3 CALB2 KIT
37 mast-cell sarcoma 10.3 KIT VIM
38 large intestine adenocarcinoma 10.3 CDH1 CTNNB1 KRT7
39 kidney hemangiopericytoma 10.3 SS18 SSX2B
40 malignant peritoneal mesothelioma 10.3 MUC1 VIM
41 adenomyoma 10.3 CTNNB1 KRT7 MUC1
42 ovarian serous cystadenofibroma 10.3 CALB2 MUC1
43 bile duct mucoepidermoid carcinoma 10.3 KRT7 MUC1
44 pleomorphic lipoma 10.3 HMGA2 MDM2
45 adenoid squamous cell carcinoma 10.3 CDH1 KRT7 VIM
46 middle ear adenoma 10.3 KRT7 MUC1
47 gynandroblastoma 10.3 CALB2 VIM
48 parachordoma 10.3 KRT7 MUC1 VIM
49 secretory meningioma 10.3 KRT7 MUC1 VIM
50 sclerosing hemangioma 10.3 CTNNB1 KRT7 MUC1

Graphical network of the top 20 diseases related to Sarcoma, Synovial:



Diseases related to Sarcoma, Synovial

Symptoms & Phenotypes for Sarcoma, Synovial

Clinical features from OMIM:

300813

Human phenotypes related to Sarcoma, Synovial:

32
# Description HPO Frequency HPO Source Accession
1 synovial sarcoma 32 HP:0012570

GenomeRNAi Phenotypes related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

26 (show top 50) (show all 55)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.29 SSX2B SSX2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.29 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.29 VIM
4 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.29 CTNNB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.29 CTNNB1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.29 IGF1R
7 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.29 SSX1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.29 IGF1R
9 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.29 VIM
10 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.29 SSX2B SSX3 SSX2 SSX1 SSX4
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.29 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.29 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.29 IGF1R
14 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.29 KIT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.29 VIM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.29 CTNNB1 IGF1R VIM
17 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.29 VIM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.29 VIM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.29 CTNNB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.29 IGF1R
21 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.29 IGF1R SSX2B SSX3 SSX4
22 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.29 SSX1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.29 VIM
24 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.29 SSX2B KIT SSX2 VIM
25 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.29 KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.29 IGF1R
27 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.29 CTNNB1 IGF1R SSX2B SSX3
28 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.29 CTNNB1 SSX4
29 Increased shRNA abundance (Z-score > 2) GR00366-A-51 10.29 SSX4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.29 SSX1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.29 VIM SSX1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.29 CTNNB1 SSX4
33 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.29 CTNNB1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.29 CTNNB1 IGF1R
35 Increased shRNA abundance (Z-score > 2) GR00366-A-76 10.29 SSX2B SSX3 SSX2
36 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.29 SSX3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.29 CTNNB1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.29 SSX2B SSX2
39 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.29 SSX4
40 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.29 IGF1R KIT VIM
41 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.29 KIT
42 Increased shRNA abundance (Z-score > 2) GR00366-A-92 10.29 SSX3
43 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.29 KIT
44 Decreased shRNA abundance (Z-score < -2) GR00366-A-1 10 SSX2
45 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10 SSX4
46 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10 SSX2B SSX3 SSX4 VIM
47 Decreased shRNA abundance (Z-score < -2) GR00366-A-15 10 KRT19
48 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 10 SSX2 SSX2B
49 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 10 SSX1
50 Decreased shRNA abundance (Z-score < -2) GR00366-A-212 10 VIM

MGI Mouse Phenotypes related to Sarcoma, Synovial:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.5 CDH1 CTNNB1 ELF3 IGF1R KIT KRT19
2 embryo MP:0005380 9.23 CDH1 CTNNB1 IGF1R KIT KRT19 MDM2

Drugs & Therapeutics for Sarcoma, Synovial

Drugs for Sarcoma, Synovial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
4
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
5
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
8
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
10
Vincristine Approved, Investigational Phase 3,Phase 2 57-22-7, 2068-78-2 5978
11
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
12
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
13
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
14
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
15
Idarubicin Approved Phase 3 58957-92-9 42890
16
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
17
Cyproheptadine Approved Phase 3 129-03-3 2913
18
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
19 Trofosfamide Investigational Phase 3 22089-22-1
20
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
22 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
23 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
24 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
25 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
26 Etoposide phosphate Phase 3,Phase 2
27 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
28 Immunologic Factors Phase 3,Phase 1,Phase 2
29 Anti-Infective Agents Phase 3,Phase 1,Phase 2,Not Applicable
30 Antimitotic Agents Phase 3,Phase 2
31 Antirheumatic Agents Phase 3,Phase 2,Phase 1
32 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
33 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
34 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
35 Antimetabolites Phase 3,Phase 2,Phase 1
36 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
37 Vaccines Phase 3,Phase 1,Phase 2
38 Serotonin Agents Phase 3
39 Anti-Allergic Agents Phase 3
40 Serotonin Antagonists Phase 3
41 Histamine H1 Antagonists Phase 3
42
Histamine Phosphate Phase 3 51-74-1 65513
43 Antipruritics Phase 3
44 Neurotransmitter Agents Phase 3
45 Dermatologic Agents Phase 3
46 Histamine Antagonists Phase 3
47 Gastrointestinal Agents Phase 3
48
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
49
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
50
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
6 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
7 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
8 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
10 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
11 A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Recruiting NCT03016819 Phase 3 AL 3818;Dacarbazine
12 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
13 Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma Recruiting NCT00876031 Phase 3 trofosfamide, idarubicin, etoposide
14 Synovate Study for Synovial Sarcoma, Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma Active, not recruiting NCT03520959 Phase 3
15 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
16 Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin Not yet recruiting NCT03773510 Phase 3 Trabectedin discontinuation;Trabectedin continuation
17 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Suspended NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
18 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
19 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
20 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
21 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
22 Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma Completed NCT00052754 Phase 2 gefitinib
23 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma Completed NCT00104949 Phase 2
24 Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma Completed NCT01281865 Phase 1, Phase 2 everolimus;imatinib mesylate
25 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
26 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Completed NCT00668148 Phase 2
27 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
28 Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure Completed NCT01136499 Phase 2 LBH589 (Panobinostat®)
29 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
30 Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
31 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
32 Ixabepilone in Treating Young Patients With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
33 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
34 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
35 Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood Completed NCT00030667 Phase 2 imatinib mesylate
36 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
37 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
38 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
39 Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma Completed NCT00297258 Phase 2 pazopanib
40 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
41 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
42 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
43 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
44 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
45 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
46 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
47 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
48 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
49 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
50 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate

Search NIH Clinical Center for Sarcoma, Synovial

Cochrane evidence based reviews: sarcoma, synovial

Genetic Tests for Sarcoma, Synovial

Genetic tests related to Sarcoma, Synovial:

# Genetic test Affiliating Genes
1 Synovial Sarcoma 29 SSX1 SSX2

Anatomical Context for Sarcoma, Synovial

MalaCards organs/tissues related to Sarcoma, Synovial:

41
Lung, T Cells, Bone, Kidney, Thyroid, Liver, Prostate

Publications for Sarcoma, Synovial

Articles related to Sarcoma, Synovial:

(show top 50) (show all 1224)
# Title Authors Year
1
Localized synovial sarcoma of the foot or ankle: A series of 32 Cooperative Weichteilsarkom Study Group patients. ( 30421433 )
2019
2
Synovial sarcoma of bone: Sarcoma typically of soft tissues presenting as a primary bone tumor. ( 30425775 )
2019
3
miR‑494.3p expression in synovial sarcoma: Role of CXCR4 as a potential target gene. ( 30431073 )
2019
4
Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases. ( 29225052 )
2018
5
Mediastinal monophasic synovial sarcoma with pericardial extension causing hemodynamic instability. ( 29765618 )
2018
6
Establishment and characterization of the NCC-SS1-C1 synovial sarcoma cell line. ( 29450702 )
2018
7
Extracellular vesicle-encapsulated microRNA-761 enhances pazopanib resistance in synovial sarcoma. ( 29191657 )
2018
8
Primary Gastric Synovial Sarcoma Mimicking a Gastrointestinal Stromal Tumor (GIST) : Gastric Synovial Sarcoma. ( 29313287 )
2018
9
Laser capture microdissection for detecting the expression of epithelial-mesenchymal transition-related genes in epithelial and spindle cells of paraffin-embedded formalin-fixed biphasic synovial sarcoma. ( 29575169 )
2018
10
Synovial sarcoma mimicking a thoracic dumbell schwannoma- a case report. ( 29446979 )
2018
11
The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients. ( 29280411 )
2018
12
Treatment of cardiac synovial sarcoma: experience of two cases. ( 29970129 )
2018
13
Synovial sarcoma of the aortopulmonary window. ( 30467895 )
2018
14
Primary biphasic synovial sarcoma of the right atrium. ( 26178188 )
2018
15
Primary thyroid biphasic synovial sarcoma and synchronous papillary carcinoma: report of a remarkable case. ( 30546147 )
2018
16
Giant primary pericardial synovial sarcoma in an adolescent with cardiac tamponade: Contrast-enhanced CT and 18F-FDG PET/CT findings. ( 30088197 )
2018
17
Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. ( 30015384 )
2018
18
Malignant Tenosynovial Giant Cell Tumor: The True "Synovial Sarcoma?" A Clinicopathologic, Immunohistochemical, and Molecular Cytogenetic Study of 10 Cases, Supporting Origin from Synoviocytes. ( 30206409 )
2018
19
Metachronous Synovial Sarcoma After Treatment of Mixed Germ Cell Tumor in a Child with Complete Gonadal Dysgenesis. ( 28836496 )
2018
20
Synovial sarcoma of the transverse colon: a rare cause of intussusception. ( 29602893 )
2018
21
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. ( 30126857 )
2018
22
Canonical Wnt/β-catenin signaling activation in soft-tissue sarcomas: A comparative study of synovial sarcoma and leiomyosarcoma. ( 30505422 )
2018
23
Human Leukocyte Antigen-A Allele Distribution in Nasopharyngeal Carcinoma Patients Showing Anti-Melanoma-Associated Antigen A or Synovial Sarcoma X-2 T Cell Response in Blood. ( 29786040 )
2018
24
PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy. ( 30524904 )
2018
25
A Case of Primary Intra-abdominal Synovial Sarcoma. ( 30538407 )
2018
26
Synovial sarcoma of the ethmoid sinus. ( 30352776 )
2018
27
Primitive synovial sarcoma of suboccipital region in child. ( 30386549 )
2018
28
Pulmonary synovial sarcoma. ( 30386721 )
2018
29
Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review. ( 30388821 )
2018
30
Surgical excision and not chemotherapy is the most powerful modality in treating synovial sarcoma: the UK's North East experience. ( 30406818 )
2018
31
Synovial sarcoma of the brachial plexus - a rare tumor in a rare area: a case report. ( 30409199 )
2018
32
Primary Synovial Sarcoma of the Mediastinum in an 18-year old male: A case report. ( 30410155 )
2018
33
Synovial sarcoma diagnosis on fine needle cytology sample confirmed by fluorescence in situ hybridisation. ( 30417957 )
2018
34
Clinicopathological features, treatment and survival outcomes of synovial sarcoma. ( 30430100 )
2018
35
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. ( 30431433 )
2018
36
Pazopanib-induced changes in protein expression signatures of extracellular vesicles in synovial sarcoma. ( 30454707 )
2018
37
Laryngeal synovial sarcoma: Report of 2 cases. ( 30482506 )
2018
38
Aortic saddle embolism following pneumonectomy for synovial sarcoma of lung. ( 30484940 )
2018
39
Targeting Regulation of Cyclin Dependent Kinase 9 as a Novel Therapeutic Strategy in Synovial Sarcoma. ( 30488489 )
2018
40
Synovial sarcoma: when epigenetic changes dictate tumour development. ( 30506527 )
2018
41
Synovial Sarcoma of the Thyroid Gland, Diagnostic Pitfalls and Clinical Management. ( 30194178 )
2018
42
Genetic and molecular reappraisal of spindle cell adamantinoma of bone reveals a small subset of misclassified intraosseous synovial sarcoma. ( 30206413 )
2018
43
Neutrophil/lymphocyte ratio is associated with survival in synovial sarcoma. ( 30217318 )
2018
44
In silico and in vitro screening of small molecule Inhibitors against SYT-SSX1 fusion protein in synovial sarcoma. ( 30219714 )
2018
45
Intra-articular synovial sarcoma in the ankle joint: A case report. ( 30233799 )
2018
46
Deep learning approach for survival prediction for patients with synovial sarcoma. ( 30261823 )
2018
47
Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model. ( 30275182 )
2018
48
Synovial sarcoma of cervicodorsal spine: A case report. ( 30317311 )
2018
49
Release of circulating tumor cells and cell-free nucleic acids is an infrequent event in synovial sarcoma: liquid biopsy analysis of 15 patients diagnosed with synovial sarcoma. ( 30326929 )
2018
50
A rare case of 18F-FDG avid cardiac synovial sarcoma. ( 30042054 )
2018

Variations for Sarcoma, Synovial

Cosmic variations for Sarcoma, Synovial:

9 (show all 20)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM43687 TP53 soft tissue,leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 13
2 COSM11333 TP53 soft tissue,leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 13
3 COSM4774989 SH2B3 soft tissue,leg,sarcoma,NS c.232G>A p.E78K 12:111418377-111418377 13
4 COSM6954536 NUP93 soft tissue,leg,sarcoma,NS c.116C>T p.A39V 16:56748363-56748363 13
5 COSM2923082 ANKRD11 soft tissue,leg,sarcoma,NS c.2882G>T p.R961L 16:89283660-89283660 13
6 COSM121083 soft tissue,leg,sarcoma,NS c.220C>T p.Q74* 17:7675113-7675113 13
7 COSM1640840 soft tissue,leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 13
8 COSM307279 soft tissue,leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 13
9 COSM2744872 soft tissue,leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 13
10 COSM3937613 soft tissue,leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 13
11 COSM307282 soft tissue,leg,sarcoma,NS c.362A>G p.H121R 17:7674890-7674890 13
12 COSM121082 soft tissue,leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 13
13 COSM121084 soft tissue,leg,sarcoma,NS c.103C>T p.Q35* 17:7675113-7675113 13
14 COSM3388198 soft tissue,leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 13
15 COSM121081 soft tissue,leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 13
16 COSM307280 soft tissue,leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 13
17 COSM307281 soft tissue,leg,sarcoma,NS c.245A>G p.H82R 17:7674890-7674890 13
18 COSM480 HRAS soft tissue,lower leg,synovial sarcoma,NS c.34G>A p.G12S 11:534289-534289 8
19 COSM1745010 MYOD1 soft tissue,lower leg,rhabdomyosarcoma,spindle cell c.365T>G p.L122R 11:17720147-17720147 4
20 COSM33732 IDH2 soft tissue,upper leg,haemangioma,spindle cell c.515G>T p.R172M 15:90088606-90088606 4

Copy number variations for Sarcoma, Synovial from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 120197 18 21850214 21924609 Translate SS18 Synovial sarcoma

Expression for Sarcoma, Synovial

Search GEO for disease gene expression data for Sarcoma, Synovial.

Pathways for Sarcoma, Synovial

Pathways related to Sarcoma, Synovial according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

GO Terms for Sarcoma, Synovial

Cellular components related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.5 CALB2 CTNNB1 ELF3 HMGA2 KRT7 MAGEA1
2 flotillin complex GO:0016600 8.96 CDH1 CTNNB1

Biological processes related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.77 CTNNB1 HMGA2 IGF1R KIT MDM2
2 viral process GO:0016032 9.72 CTNNB1 KRT19 KRT7 MDM2 VIM
3 regulation of transcription, DNA-templated GO:0006355 9.56 CTNNB1 ELF3 HMGA2 SSX1 SSX2 SSX2B
4 positive regulation of gene expression GO:0010628 9.55 CTNNB1 HMGA2 KIT MDM2 VIM
5 entry of bacterium into host cell GO:0035635 9.26 CDH1 CTNNB1
6 cellular response to indole-3-methanol GO:0071681 8.62 CDH1 CTNNB1

Molecular functions related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 CDH1 CTAG1B CTNNB1 ELF3 HMGA2 IGF1R

Sources for Sarcoma, Synovial

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....